 |
|
|
| |
A Phase 2b Study of MK-7009 (vaniprevir) in Patients with Genotype 1 HCV Infection Who HaveFailed Previous Pegylated Interferon and Ribavirin Treatment
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
Eric Lawitz1, Maribel Rodriguez-Torres2, Albrecht Stoehr3, Edward J. Gane4, Lawrence Serfaty5, Sanhita Bhanja6, Richard J. Barnard6, Di An6, Jacqueline Gress6, Peggy Hwang6, Niloufar Mobashery6
1Alamo Medical Research, San Antonio, TX, United States; 2Fundacion de Investigacion, San Juan, Puerto Rico; 3IFI - Institut fur Interdisziplinäre Medizin, Hamburg, Germany; 4Auckland Clinical Studies Ltd, Auckland, New Zealand;5Service d'Hepatologie, Hopital Saint-Antoine, Universite Pierre et Marie Curie, Paris, France; 6Merck and Company, North Wales, PA, United States
|
| |
|
|
|
|
|
